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ttp://dx.doi.org/10.1016/j.jmoldx.2013.05.010The BCR-ABL1 translocation is a hallmark of chronic myeloid leukemia. Because patients treated with
imatinib and other tyrosine kinase inhibitors achieve lower levels of detectable disease, quantitation of
BCR-ABL1 transcripts with quantitative RT-PCR has become an essential tool in chronic myeloid leukemia
monitoring. The prognostic signiﬁcance of molecular responses was recently established by large-scale
clinical trials. Achieving deﬁned levels of BCR-ABL1 on the International Scale within speciﬁc time
frames is an important measure for assessing patient response and probability for relapse and progres-
sion. However, extensive variation in quantitative RT-PCR procedures and reporting makes it difﬁcult to
interpret these results. More important, lack of standardization, particularly in the United States,
prevents the comparison of individual patient results to the data from the clinical trials, which thereby
prohibits the meaningful use of such results in the direction of patient care. In this article, we will present
an overview of the clinical trial discoveries that drive the need for standardization, review the most
updated monitoring guidelines by the National Comprehensive Cancer Network, and highlight recom-
mendations for laboratory practice regarding internal controls and reference materials. Finally, we will
provide an update on the recent efforts in the standardization of quantitative RT-PCR reporting using the
International Scale. (J Mol Diagn 2013, 15: 556e564; http://dx.doi.org/10.1016/j.jmoldx.2013.05.010)This article is partly based on material presented by Y.L.W. at the William
Beaumont Hospital 21st Annual Symposium on Molecular Pathology: Clin-
ical Applications of Genomic Medicine, September 19e20, 2012, Troy, MI.
Current address of Y.L.W., The University of Chicago, Chicago, IL.The treatment of chronic myeloid leukemia (CML) with
imatinib has set the paradigm in targeted cancer therapy,
transforming a once fatal malignancy into a manageable
chronic condition. Imatinib has revolutionized the treatment
of chronic myeloid leukemia by demonstrating how the
speciﬁc inhibition of a unique fusion kinase, BCR-ABL1,
can effectively curb leukemogenesis and produce early
cytogenetic and molecular responses of great depth in most
patients.1,2 The landmark International Randomized Study
of Interferon and STI571 (IRIS) trial established imatinib as
an effective ﬁrst-line therapy in CML and demonstrated the
prognostic importance of using BCR-ABL1 levels to assess
therapeutic responses.
Among the various techniques that are available, the
molecular monitoring of BCR-ABL1 with quantitative RT-
PCR (RT-qPCR, also RQ-PCR) has become essential in
assessing patient response, monitoring minimal residual
disease, and detecting relapse. However, extensive variation
in the procedures, ranging from sample collection to thestigative Pathology
.choice of an internal control and to results reporting, has
prohibited the interlaboratory comparability of RT-qPCR
results. More important, the lack of standardization, partic-
ularly in the United States, makes it difﬁcult to align indi-
vidual results with the clinical trial data to determine
whether a patient response is adequate and to direct next-
step patient care. Therefore, standardization of RT-qPCR
is imperative for the management of CML and conduction
of clinical studies of novel agents in CML.
In recent years, the international BCR-ABL1 standardi-
zation group has made efforts to standardize the procedures
and reporting of RT-qPCR results. In this article, we will
review the clinical trial discoveries that propel the need for
standardization, present an overview of current monitoring
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Figure 1 Diagram of how BCR-ABL1 transcript levels change with
tyrosine kinase inhibitor treatment over time. Responding patients expe-
rience a continuum of therapeutic milestones. CHR, complete hematolog-
ical response; CMR, CMR representing 0.032%IS; Ctrl, control; MMR, MMR
representing 0.1%IS. Asterisk, the 100% standardized baseline deﬁned by
the mean transcript level in a pool of 30 diagnostic CML specimens used in
the IRIS trial (see Reference Materials).
Standardization of BCR-ABL1 Quantitationguidelines, and highlight recommendations for laboratory
practice regarding appropriate internal and external controls.
Finally, we will provide an update on the recent efforts in
the standardization of RT-qPCR reporting using the Inter-
national Scale (IS).
The Prognostic Signiﬁcance of BCR-ABL1
Quantitation Has Been Established in Multiple
Clinical Trials
CML is recognized as one of the ﬁrst neoplastic disorders
directly linked to a genetic abnormality. The cytogenetic
hallmark of CML is the Philadelphia (Ph) chromosome,3
which is a result of chromosomal translocation, t(9:22)
(q34:q11.2).4 This translocation is found in nearly all patients
with CML and in 30% to 40% of Phþ patients with acute
lymphoblastic lymphoma at diagnosis. It produces a BCR-
ABL1 fusion with an abnormal tyrosine kinase activity that
promotes the characteristic proliferation of progenitor cells
in CML and acute lymphoblastic lymphoma. BCR-ABL1
kinase signaling constitutively activates downstream pro-
teins that promote growth factor-independent proliferation,
altered adhesion, resistance to DNA repair, and inhibition of
apoptosis that culminates in the malignant transformation of
hematopoietic stem cells.5 The BCR-ABL1 fusion transcript
and its resulting kinase have become a key target and
biomarker in the treatment and monitoring of CML.
The targeting of BCR-ABL1 fusion kinase was the ﬁrst
successful paradigm of molecularly targeted therapy. The
discovery of STI571 (imatinib mesylate), a selective ABL
tyrosine kinase inhibitor that speciﬁcally blocks BCR-ABL1
signaling activity by competing for ATP binding, revolu-
tionized the treatment of CML.1 The pivotal IRIS trial
demonstrated that hematological, cytogenetic, and molec-
ular remissions were reached faster with imatinib than any
previous ﬁrst-line therapy for CML.2,6,7
Patients with CML undergoing treatment are monitored
in laboratories by bone marrow (BM) cytogenetic analysis,
ﬂuorescence in situ hybridization (FISH), and RT-qPCR.
BM cytogenetics and FISH remain as gold standards for
this purpose, providing clinicians with an accurate assess-
ment of the disease at the chromosomal level. However,
because more patients taking imatinib regularly achieve
deep responses with fewer detectable leukemic (Phþ) cells,
cytogenetics and FISH analyses have become limited in
providing information on the kinetics of low-level dis-
ease.8e10 RT-qPCR has emerged as the most sensitive test
available,11e14 capable of detecting one leukemic cell in
approximately 105 to 106 normal cells.
Therapeutic Milestones in the Treatment of CML
A 7-year IRIS trial update demonstrated a continuous decrease
in the number of fusion transcripts in patients taking imatinib
during the 7-year period, showing anongoing reduction of theirThe Journal of Molecular Diagnostics - jmd.amjpathol.orgleukemic cell burden with treatment.7 An illustration of how
BCR-ABL1 levels change with treatment over time is shown in
Figure 1. Patients responding to imatinib treatment achieve
a continuum of response milestones.15 A complete hemato-
logical response is generally expected at 3 months and is
characterized by the complete normalization of peripheral
blood (PB) counts and spleen size.2,6,16 This is followed by
a complete cytogenetic response (CCyR), deﬁned by the
absenceofPhþmetaphasesonaBMcytogenetics examination.
Patients who achieve a CCyR, at any point in therapy, are
associated with more durable and favorable responses.17,18
Despite this, the use of RT-qPCR has revealed additional
levels of molecular response with prognostic implications in
themanagement ofCML.Amajormolecular response (MMR)
is a 3-log reduction in BCR-ABL1 compared with a standard-
ized baseline value set by the IRIS trial (or0.1%on the IS)8,19
(Figure 1). Achieving a CCyR alongside an MMR is widely
accepted as a desirable therapeutic response that projects
durable long-term survival and reduced risk for relapse and
progression.7,20 A complete molecular response (CMR) is the
lowest deﬁned level of therapeutic response and represents
a 4.5-log reduction from the IRIS baseline.
MMR Data
The prognostic signiﬁcance of molecular responses was
deﬁned in the IRIS trial.2,7,8 A 1-log decrease in BCR-ABL1IS
every 6 months was considered an adequate response.
Patients, who obtained a BCR-ABL1 level of 10%IS at 6
months, had an event-free survival (EFS) of 85% and
a progression-free survival (PFS) of 95% at 7 years,
compared with 56% and 76%, respectively, in those who did
not. Patients with an BCR-ABL1 1.0%IS at 12 months had
an EFS of 91% and a PFS of 95%, compared with 64%
and 83%, respectively, in those with higher levels of BCR-
ABL1. More important, obtaining a BCR-ABL1 of 0.1%IS
or an MMR at 18 months was a prognostically signiﬁcant
event, with an EFS of 95% and a PFS of 99% at 7 years,557
Zhen and Wangcompared with 75% and 90%, respectively, in those without
an MMR. To date, no patient in the IRIS trial with an MMR
by 12 or 18 months has progressed to the accelerated phase
(AP) or blast crisis (BC).
These therapeutic milestones set forth by the IRIS trial also
proved to be good prognostic indicators in the phase 3 trials
involving second-generation tyrosine kinase inhibitors
(TKIs). In the Evaluating Nilotinib Efﬁcacy and Safety in
Clinical Trials-Newly Diagnosed Patients (ENESTnd) and
Dasatinib Versus Imatinib Study in Treatment-Naïve CP-
CML Patients (DASISION) trials, which determine the efﬁ-
cacy and safety of nilotinib and dasatinib asﬁrst-line therapies,
respectively, MMR was used either as a primary (ENESTnd)
or a secondary (DASISION) end point for evaluation. The
results of these phase 3 trials corroborated the prognostic
signiﬁcance of MMR achievement. In the ENESTnd trial,
almost twice as many patients acquired MMR at 12 months
while taking nilotinib compared with those taking imatinib.21
This higher rate of molecular response is associated with
a signiﬁcantly lower rate of progression to AP and BC in
aminimum follow-up of 3 years.22 In the DASISION trial, 1.6
times more patients acquiredMMR at 12 months while taking
dasatinib than those taking imatinib.23 This also corresponded
to an approximately 50% lower rate of transformation to AP
and BC.24 These clinical trials suggest that achieving MMR
within the 12-month time frame is prognostically signiﬁcant in
determining a durable response to TKI therapy without
progression. A failure to reach these landmark responses
portends a developing resistance to TKI or noncompliance and
may prompt a reassessment of therapy. Therefore, BCR-ABL1
levels should be used to identify patients with a suboptimal
response and patients at a higher risk for progression,whomay
beneﬁt from a switch to second-line therapies.
CMR Data
A CMR is deﬁned as undetectable BCR-ABL1 mRNA by
qPCR using an assay with a sensitivity of at least 4.5 logsTable 1 NCCN Guidelines for the Monitoring of CML in Patients Taking
Indication Testing
At diagnosis before therapy RT-qPCR and BM cytoge
If BM is not feasible, FI
During therapy RT-qPCR
BM cytogenetics
ABL kinase domain muta
After complete cytogenetic response RT-qPCR
BM cytogenetics to dete
FISH is not recommende
Increasing levels of BCR-ABL1 transcripts Evaluate compliance
Repeat RT-qPCR in those
BM cytogenetics in thos
Consider ABL kinase dom
Summarized from National Comprehensive Cancer Network (NCCN) Clinical Practi
Version 3.2013 (section CML-A, page 15; http://www.nccn.org/professionals/physic
558lower than the standardized baseline (or <0.0032%IS) [Na-
tional Comprehensive Cancer Network (NCCN) Clinical
Practice Guidelines in Oncology (NCCNGuidelines) Chronic
Myelogenous Leukemia Version 3.2013, section CML-J,
page 24; http://www.nccn.org/professionals/physician_gls/
pdf/cml.pdf, last accessed May 31, 2013; requires user regis-
tration]. The clinical signiﬁcance of CMR is unclear. A
minority of patients taking imatinib have displayed an
extended period of undetectable BCR-ABL1 or CMR, raising
the possibility that they may be potential candidates for the
discontinuation of imatinib.25,26 However, the prognostic
signiﬁcance of a CMR has not been fully established. A sus-
tained CMR should not be interpreted as a cure or eradication
of all leukemic cells because it merely represents the lowest
limit of analytical sensitivity of theRT-qPCR assay.27 Patients
with a CMR may still have fewer (approximately 106 to 107)
leukemic cells that may repopulate in the absence of TKIs.19,28
Clinical trials, such as theStop Imatinib study, have shown that
61% of patients, who had a CMR for at least 2 years, had
a molecular relapse within the ﬁrst year of stopping imatinib
therapy.25 Those who relapsed responded well to the reintro-
duction of imatinib and eventually regained their CMR or
displayed decreasing levels of BCR-ABL1. Imatinib needs to
be taken for an indeﬁnite period, even after patients achieve
CMR, until clinical trials prove otherwise.NCCN Guidelines on Monitoring Frequencies
Based on the prognostic importance of molecular responses
established by the IRIS and subsequent trials on TKI thera-
pies, the National Comprehensive Cancer Network (NCCN)
has provided and updated guidelines for the frequencies of
molecular monitoring in patients treated with TKIs. Patients
should be monitored with vigilance at the highest frequency
in the ﬁrst 2 to 3 years of TKI therapy, because adverse
events, including loss of response and disease trans-
formation, are more likely to occur in this early period.29Tyrosine Kinase Inhibitors
Frequency
netics
SH on PB is acceptable
Every 3 months
At 3, 12, and 18 months until CCyR
or MMR is achieved
tion analysis When initial response is inadequate
Every 3e6 months
ct clonal evolution As clinically indicated
d
As clinically indicated
with MMR
e without MMR
ain mutation analysis
ce Guidelines in Oncology (NCCN Guidelines) Chronic Myelogenous Leukemia
ian_gls/pdf/cml.pdf, last accessed May 31, 2013; requires user registration).
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RT-qPCR
Cell Preparation* 
RNA Preparation
PB Specimens Collection
Reverse Transcription into cDNA
qPCR of BCR-ABL1 and the Internal Control Gene
with Standard Curves
with Reference Materials**
Data Analysis and Reporting
Figure 2 The principal steps of the RT-qPCR procedure. Most labora-
tories isolate total white blood cells by performing a simple step of red cell
lysis (single asterisk). qPCR of BCR-ABL1 and the control gene are normally
performed in parallel in the same run, and duplicate analysis of the stan-
dard curves, references, and patient materials is normally required for
accurate quantiﬁcation (double asterisks).
Standardization of BCR-ABL1 QuantitationWe summarized the NCCN, version 1.2013, guidelines
regarding BCR-ABL1 monitoring schedules in Table 1. At
diagnosis before treatment, a baseline BM cytogenetics anal-
ysis and a PB RT-qPCR are recommended to identify the Ph
chromosome and detectable BCR-ABL1 fusion transcript to
conﬁrm a diagnosis of CML.12,28 If a BM specimen is not
obtainable, an FISH performed on PB is acceptable. During the
course of TKI treatment, BM cytogenetics should be obtained
at 3, 12, and 18 months to conﬁrm the reduction in Phþ cells.
RT-qPCR is recommended every 3 months before CCyR and
every 3 to 6 months once CCyR is achieved.30 FISH is not
recommended during this stage ofmonitoring unlessRT-qPCR
is not available. Good responders to the TKI are expected to
achieve the molecular response milestones at 6, 12, and 18
months; these milestones are associated with better long-term
survival and freedom from progression, as deﬁned by the
clinical trials (previously described).
At any point during therapy, a failure to respond to a TKI
is manifested by increasing BCR-ABL1 levels. Patients with
a 1-log increase in their BCR-ABL1 should ﬁrst be
checked for compliance. After noncompliance is excluded,
in those patients with an MMR, a repeat RT-qPCR should
be conducted to conﬁrm the increasing transcript level.
Repeat conﬁrmation is needed because, at levels lower than
an MMR, technical variation may cause a false increase. In
patients without an MMR, a 1-log increase should prompt
a BM cytogenetics evaluation for additional chromosomal
abnormalities indicative of clonal evolution that may
proceed to disease progression or transformation. When
a true 1-log increase is conﬁrmed, an ABL kinase domain
mutation analysis is advised to identify any underlying
mutations, rendering the BCR-ABL1 kinase resistant to TKI
inhibition.
Several BCR-ABL1 mutants have been identiﬁed to be
highly refractory to imatinib.31e35 Mutations in the P-loop of
the kinase domain, in particular, have been associated with
poorer prognosis.36,37 Alerting clinicians to the possible need
to change therapy is important because nilotinib and dasati-
nib remain effective against most forms of mutated ABL
kinase, with the exception of BCR-ABL1T315I.34,36,38,39
Fortunately, this particular mutant responds well to ponati-
nib, which is a third generation of TKI recently approved by
the Food and Drug Administration in December 2012 for the
treatment of patients with CML resistant or intolerant to other
prior TKI therapies.40 Similar to the relationship between
adverse events and time taking imatinib, the incidence of
mutations was also found to occur at higher frequencies in the
ﬁrst 2 years of therapy, at least for nilotinib and dasatinib.28
As such, accurate monitoring of BCR-ABL1 transcript
levels has become invaluable in predicting patient
response41,42 or resistance to imatinib and second-generation
TKIs. For molecular testing results to become practical
information that affects management decisions, it is imper-
ative to standardize RT-qPCR to permit comparison of
individual laboratory results to the IRIS data and to enable
clinical practice following NCCN guidelines.43The Journal of Molecular Diagnostics - jmd.amjpathol.orgStandardization of the Multistep RT-qPCR
Although there is an ongoing effort toward implementing
international standardization, many different forms of RT-
qPCR testing exist. RT-qPCR is a technically challenging
multistep technique (Figure 2). Differences in sample col-
lection, cell preparation, RNA isolation, RT, internal control
selection, standard curve construction, and data reporting
all contribute to the outstanding variation found in the re-
ported BCR-ABL1 data. This wide variation among different
laboratories, particularly in the United States, was ﬁrst
revealed by surveys conducted among members of the
Association for Molecular Pathology44 and then by the
College of American Pathologists (CAP) surveys. In one of
the ﬁrst surveys conducted in 2006, 34 member laboratories
tested the same two samples for BCR-ABL1 and produced
34 values in different units, with numerical numbers span-
ning 7 logs for each sample, as revealed by our analysis. Six
years later, in 2012, analysis of the CAP data shows that
results from 143 laboratories on the sample, with the highest
BCR-ABL1 content, still have striking differences; the high-
est reported value was approximately 500,000-fold higher
than the lowest reported value, even when all values were
reported as a ratio of target/control.45
This widespread variation has caused tremendous
confusion among patients and hematologists.43 In clinical559
Zhen and Wangpractice, it is not uncommon for patients to relocate or to
change their insurance, thereby necessitating a change in
their testing laboratory. The poor interlaboratory compara-
bility makes the management of patient care difﬁcult when
a patient’s previous BCR-ABL1 values are not comparable
to subsequent measurements at the new testing site. In
addition, it is crucial for the hematologists to relate indi-
vidual patient values, determined by a particular laboratory,
to those of the clinical trial milestones because the prog-
nostic relevance of reaching these time-dependent thera-
peutic milestones has been established and should be used
to direct clinical management. Regardless of testing site,
a CML patient’s level of BCR-ABL1 must be properly
aligned to the IS that is associated with long-term survival
information (described previously).
To initiate standardization, representatives from several
leading academic institutions and hospitals were gathered at
the NIH (Bethesda, MD) in 2005 to form the international
RT-qPCR standardization group; they discussed recom-
mendations toward harmonizing the different RT-qPCR
methods that were in use.46 The group proposed recom-
mendations for each vital step in the RT-qPCR procedure,
including the following: i) proper collection of patient
specimens, ii) cell preparation, iii) selection of enzyme and
primers for the step of RT, iv) selection of an internal
control gene for PCR, v) appropriate construction of a PCR
standard curve, and vi) the adoption of a standardized IS for
reporting. In addition, directions and strategies for the
development of external reference materials were dis-
cussed.46,47 Readers are referred to Hughes et al46 and
Branford et al47 for recommendations regarding each of the
principal RT-qPCR steps. In reality, however, it is imprac-
tical to have all testing laboratories abandon their current
testing methods to adopt the same RT-qPCR method. Two
key issues are essential to the process of standardization: the
internal control gene and external reference materials.
Below, we will focus on the recommendations regarding
these two essential components.
Internal Control
The quantitation of leukemic burden is often reported as
a ratio/percentage of BCR-ABL1 to an internal control gene.
As such, internal controls serve as internal calibers to
normalize BCR-ABL1 levels and control for RNA loss, in
both quantity and quality, from the step of sample collection
to the step of cDNA qPCR. In a clinical setting, pre-
analytical steps, including the amount of blood collected,
the number of leukemic cells in the sample, and duration of
sample transport, are highly variable from patient to patient.
These difﬁcult-to-control pre-analytical factors contribute
signiﬁcantly to the variation in RNA integrity and quantity,
making the internal control the single most important factor,
among all others, for the adequate and reliable quantitation
of BCR-ABL1 levels. Branford et al48 showed that reported
transcript values, on a single specimen tested by the same560laboratory, differed by severalfold because of the use of two
different internal controls.
To determine which internal control genes are appropriate
in RT-qPCR of BCR-ABL1 (among other fusion genes), the
Europe Against Cancer group selected a set of widely used
control genes for comparison with the following criteria49: i)
an absence of pseudogenes to prohibit genomic DNA
ampliﬁcation, ii) high to medium expression, iii) similar
expression between normal PB samples and CML samples,
and iv) similar expression between PB and BM samples.
Control genes were evaluated by these criteria only in
diagnostic samples. Based on this study, ABL1 and GUSB
were recommended as reliable internal controls.
We independently conducted our own study on internal
control gene selection using six relevant criteria: some over-
lapped with the Europe Against Cancer criteria, whereas
others were distinct. The overlapping criteria included similar
expression to BCR-ABL1 and the absence of pseudogenes.
The distinct criteria emphasized the changes across multiple
samples and included the following: i) performance on serial
sample testing, ii) performance on a residual disease model,
iii) degradation kinetics compared with that of BCR-ABL1,
and iv) stability under changing cellular conditions.50,51 As
opposed to a single sample, serial sample testing and the
residual disease model involved pairs of samples and, thus,
mimicked a routine CML monitoring scenario, for which the
BCR-ABL1 quantitation is intended. These unique criteria
provided information about the properties of control genes
that are not otherwise revealed. We found GUSB to be the
most appropriate control gene for themolecularmonitoring of
CML. GUSB displayed similar BCR-ABL1 fold changes in
serial testing of paired patient samples asG6PD and TBP, two
of a total ﬁve control genes that were evaluated (including
GUSB and ABL1). GUSB also yielded the predeﬁned fold
change in BCR-ABL1 on the residual disease model made
with patient samples. Furthermore, GUSB degraded with
similar kinetics to BCR-ABL1 so that similar BCR-ABL1/
GUSB was maintained throughout the course of RNA
degradation. Last, the BCR-ABL1/GUSB ratio was maintained
the same throughout in vitro imatinib treatment of BCR-
ABL1ebearing K562 cells. Another control gene, G6PD,
performed just as well as the GUSB gene; however, frequent
mutations that affect G6PD in G6PD-deﬁcient patients from
certain populations may pose a limitation to its use.
Although ABL1 is the most widely used internal control
gene, as populated by several commercially available kits, our
studies raised concerns over its use because the primer/probe
used in the Europe Against Cancer study ampliﬁed both the
wild-type and translocatedABL1 genes. The transcript/control
gene ratio, therefore, becomes BCR-ABL1/(BCR-ABL1 þ
ABL1), where the denominator changes as the level of fusion
transcripts change with therapy. This feature underestimates
the actual amount of BCR-ABL1, especially when BCR-ABL1
levels are high at diagnosis or during the early phase of
TKI treatment. For this particular reason, the International
Standardization Group recommends against using the ISjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 2 BCR-ABL1/Control Gene Values Assigned to the
WHO-Accredited Primary Reference Materials
BCR-ABL1
Designation BCR-ABL1/ABL1 BCR-ABL1/BCR BCR-ABL1/GUSB
1 (08/192) 0.0118 0.0195 0.0071
2 (08/194) 0.1112 0.1753 0.0749
3 (08/196) 1.1672 1.6627 0.8295
4 (08/198) 10.7469 16.3129 10.1235
Data are given as percentages. Reproduced from White et al52 by
permission of the American Society of Hematology.
WHO, World Health Organization.
Standardization of BCR-ABL1 Quantitation>10% because of control gene-dependent distortions at
high disease levels.52 The problem with underestimation of
ABL1-controlled BCR-ABL1 was reﬂected in multiple proﬁ-
ciency surveys by CAP.
In later stages of therapy, this inaccuracy becomes
negligible as BCR-ABL1 decreases to <10% and the ratio
becomes BCR-ABL1/ABL1.53 Thus, ABL1 remains a viable
internal control after therapy, but only when patient BCR-
ABL1 ratio decreases to <0.1 (or 10%). Keeping this limi-
tation in mind, the International Standardization Group
recommended the following three genes, BCR, ABL, and
GUSB, as internal controls.46 Because the internal control
gene is the single most important factor in the quantitation
of the BCR-ABL1 transcript, adhering to the use of this
proven set of internal controls will assist in standardizing
BCR-ABL1 testing procedures and reporting.
Reference Materials (External Controls)
Although an appropriate internal control gene is critical in
RT-qPCR for the accurate relative comparison of samples
within a single laboratory, external controls with predeﬁned
transcript levels are ultimately required to unify laboratory-
speciﬁc measurements of BCR-ABL1 to a common stan-
dardized scale, independent of any testing laboratory and its
speciﬁc RT-qPCR method. The development of such
materials is another key issue in standardization, and these
materials would serve as a universal ruler that allows
interlaboratory comparison and comparison of individual
patient results to that of the clinical trials.
The International BCR-ABL1 Standardization Group
proposed the IS as the standardized unit for BCR-ABL1
measurements in 2005.46 This was based on the IRIS trial,
when its participating laboratories experienced the same
comparability issue involving disparate RT-qPCR data. The
baseline 100% was then deﬁned as the median transcript
value measured in a pool of 30 samples with untreated and
newly diagnosed chronic-phase CML patients enrolled in
the IRIS trial.19 A 3-log reduction from this standardized
baseline or 0.1% BCR-ABL1IS was deﬁned as an MMR, and
a 4.5-log reduction was later deﬁned as a CMR (Figure 1).
During the next few years, to help accelerate the propaga-
tion of the IS, the international group conducted two inde-
pendent studies allowing individual testing laboratories to
convert their results into IS units without having to change
their procedures: ﬁrst, by means of sample exchanges
with reference laboratories, leading to the generation of
laboratory-speciﬁc conversion factors; and second, by the
generation of reference materials with predeﬁned IS values.
It takes multiple steps to obtain and maintain a conversion
factor through sample exchanges, and this method may soon
be replaced by the reference material method. To obtain
a conversion factor, a testing laboratory conducts mutual
sample exchanges with one of several established reference
laboratories, using samples that cover a range of BCR-ABL1
values. The reference laboratories, such as the AdelaideThe Journal of Molecular Diagnostics - jmd.amjpathol.orglaboratory in Australia and the Mannheim laboratory in
Germany, maintain validated materials that can be directly
linked back to the original pool of 30 IRIS pretreatment
controls.46,47,53 The results for both laboratories are compared,
and a laboratory-speciﬁc conversion factor is then calculated
by the reference laboratories. For subsequent patient testing,
the individual laboratory can simply multiply its local BCR-
ABL1 values by the conversion factor to convert and align its
BCR-ABL1 results to IS values.
Sample exchange with the reference laboratories is effec-
tive in harmonizing results generated by different laborato-
ries. Before conversion, BCR-ABL1 values by 19 different
laboratories ranged from approximately eightfold lower to
approximately eightfold higher than the reference value.48
After the conversion to IS using laboratory-speciﬁc conver-
sion factors, there was only an average difference of
1.2-fold, where onefold indicates no difference from the
reference value.48,54 Although this method of alignment
provides an effective means toward standardization of BCR-
ABL1 testing, the generation of conversion factors is a metic-
ulous and time-consuming procedure that is only available
to a few laboratories at a given time53; it is not clear how often
the mutual sample exchange should be conducted to recali-
brate the conversion factor to ensure its accuracy over time.
Rather than using reference laboratories as external con-
trols, the other study conducted by the International Stan-
dardization Group focused on the generation of external
reference materials with the goal of distributing these
materials with predetermined BCR-ABL1IS values to indi-
vidual laboratories, allowing them to calibrate and align
their local values by themselves. The group envisioned two
kinds of reference materials being generated: primary and
secondary. The primary reference will be made in limited
quantities, tested, and validated vigorously for the accredi-
tation by the World Health Organization. These accredited
primary materials will then be distributed to manufacturers
for them to use as calibrators for the generation of secondary
reference materials. The latter will be produced in large
amounts to sustain repetitive routine use by individual
testing laboratories on an ongoing basis.
The formulation of primary reference materials is not
straightforward, and a small-scale pilot study was ﬁrst
conducted to determine how the primary reference materials
should be generated. An ideal reference material should561
Zhen and Wangclosely resemble and behave like actual patient samples,
controlling for all steps of the RT-qPCR procedure while
remaining stable over extended periods of storage. Refer-
ence materials with different levels of BCR-ABL1 were
made by mixing wild-type and mutant-containing compo-
nents at deﬁned ratios. As for the raw materials for mixing,
BCR-ABL1econtaining or BCR-ABL1elacking cells, RNA,
chemically stabilized armored RNA, cDNA, and plasmid
DNA were all considered. Using RNA proved to be not
ideal given its unstable nature, whereas cDNA and plasmid
DNA were not involved in some of the principal steps in the
RT-qPCR procedure; therefore, they could not gauge those
steps for their efﬁciency. In addition, plasmid controls could
be an external source of contamination during PCR setup.
Cells were eventually selected as the materials to generate
primary references because they control for all steps of RT-
qPCR, including RNA extraction, and stable forms can be
made by the lyophilization of cells.55 In addition, cell-based
materials are compatible with all existing RT-qPCR
methods for BCR-ABL1 determination. Cell-based refer-
ence materials containing K562 mixed with 30 different
BCR-ABL1elacking cell lines were then tested. To accom-
modate the three recommended internal control genes,
HL60 was eventually selected to mix with K562, because it
expressed BCR, ABL1, and GUSB at comparable levels to
those found in normal leukocytes.52
Four 10 dilutions of K562 with HL60 were generated.
On successful trials in several laboratories, a large-scale cell
mixture was produced, lyophilized, tested for stability and
homogeneity, and distributed to participating laboratories
with established conversion factors for BCR-ABL1 quanti-
tation. Based on the mean values obtained from these labo-
ratories, each reference material was assigned a value of 10%,
1%, 0.1% (MMR), or 0.01% BCR-ABL1/control gene (%)
on the IS (Table 2).52 The lyophilized cell mixtures are
stable for long-term storage over a wide range of tempera-
tures from 150C to 45C. These materials and testing
results were presented to the World Health Organization for
accreditation and were approved by the World Health
Organization Expert Committee on Biological Standardiza-
tion in November 2009 as the ﬁrst World Health Organiza-
tion International Genetic Reference Panel for the quantitation
of BCR-ABL1mRNA (World Health Organization document,
World Health Organization/BS/09.2106).52
It is important to keep in mind that the caveat is not to use
these materials to deduce BCR-ABL1 measurements of
>10%. The IS is only valid at 10% because of the
nonlinearity of ABL-controlled BCR-ABL1 values at high
levels.50,51,56
These accredited primary materials have become available
through the National Institute for Biological Standards and
Controls (code 09/138). In addition, the National Institute for
Biological Standards and Controls published on its website
its suggested method for the calibration of secondary refer-
ence material (WHO International Standard: 1st WHO
International Genetic Reference Panel for quantitation of562BCR-ABL translocation by RQ-PCR, page 3; http://www.
nibsc.org/documents/ifu/09-138.pdf, last accessed May 31,
2013). Since then, the commercial production of secondary
materials has been attempted by several manufacturers.
However, no independent studies have demonstrated which
secondary reference materials provide the most accurate
BCR-ABL1IS values.
Our analysis of the ﬁrst 2012 CAP surveys revealed that
the reported BCR-ABL1IS values on a single sample ranged
from 0.16% to 39% among 13 laboratories using the same
commercial RT-qPCR kit with IS calibrators. These results
would be confusing if the surveyed sample was a real
patient sample, in which one result would suggest the
patient is responding well by approaching an MMR and the
other would suggest that the patient has a minimal response
to treatment. At the present time, it is not clear what causes
these discrepancies. Notably, among the 13 laboratories,
many reported IS values >10%,45 which is clearly against
the current International Group recommendations.52 These
observations suggest that with all of the efforts that have
been made so far in the standardization of RT-qPCR, there
remains some distance for laboratories to travel to reach
uniﬁed BCR-ABL1 testing and reporting.
Summary
In summary, molecular response measured by BCR-ABL1
RT-qPCR provides important prognostic information for the
management of patients with CML treated with TKI thera-
pies. The NCCN has developed guidelines to help hema-
tologists monitor patients with CML to determine whether
they obtain adequate responses within particular time
frames. Standardization of testing and reporting across
different laboratories is necessary to provide meaningful
BCR-ABL1 RT-qPCR results. Progress has been made in the
past several years in the standardization of the internal
control genes and external reference materials. In the future,
continued efforts are to be made in the generation and
evaluation of secondary reference materials and in the
incorporation of these materials into routine testing to
enable uniﬁed reporting of BCR-ABL1 levels on the IS.References
1. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S,
Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl
tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med
1996, 2:561e566
2. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M,
Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T,
Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J,
Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K,
Verhoef G, Bolton AE, Capdeville R, Druker BJ: Imatinib compared
with interferon and low-dose cytarabine for newly diagnosed chronic-
phase chronic myeloid leukemia. N Engl J Med 2003, 348:994e1004
3. Nowell PC, Hungerford DA: Minute chromosome in human chronic
granulocytic leukemia. Science 1960, 132:1497jmd.amjpathol.org - The Journal of Molecular Diagnostics
Standardization of BCR-ABL1 Quantitation4. Rowley JD: Letter: a new consistent chromosomal abnormality in
chronic myelogenous leukaemia identiﬁed by quinacrine ﬂuorescence
and Giemsa staining. Nature 1973, 243:290e293
5. Druker BJ: Translation of the Philadelphia chromosome into therapy
for CML. Blood 2008, 112:4808e4817
6. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H,
Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM,
Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P,
Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G,
Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP,
Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA:
Five-year follow-up of patients receiving imatinib for chronic
myeloid leukemia. N Engl J Med 2006, 355:2408e2417
7. Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS,
Foroni L, Druker BJ, Guilhot F, Larson RA, O’Brien SG,
Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP:
Long-term prognostic signiﬁcance of early molecular response to
imatinib in newly diagnosed chronic myeloid leukemia: an analysis
from the International Randomized Study of Interferon and STI571
(IRIS). Blood 2010, 116:3758e3765
8. Branford S: Chronic myeloid leukemia: molecular monitoring in clinical
practice. Hematology Am Soc Hematol Educ Program 2007:376e383
9. Branford S, Hughes TP, Rudzki Z: Monitoring chronic myeloid
leukaemia therapy by real-time quantitative PCR in blood is a reliable
alternative to bone marrow cytogenetics. Br J Haematol 1999, 107:
587e599
10. Kantarjian HM, Talpaz M, Cortes J, O’Brien S, Faderl S, Thomas D,
Giles F, Rios MB, Shan J, Arlinghaus R: Quantitative polymerase
chain reaction monitoring of BCR-ABL during therapy with imatinib
mesylate (STI571; gleevec) in chronic-phase chronic myelogenous
leukemia. Clin Cancer Res 2003, 9:160e166
11. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A,
Berger U, Hehlmann R, Cross NC, Hochhaus A: Accurate and rapid
analysis of residual disease in patients with CML using speciﬁc
ﬂuorescent hybridization probes for real time quantitative RT-PCR.
Leukemia 1999, 13:1825e1832
12. Kantarjian H, Schiffer C, Jones D, Cortes J: Monitoring the response
and course of chronic myeloid leukemia in the modern era of BCR-
ABL tyrosine kinase inhibitors: practical advice on the use and
interpretation of monitoring methods. Blood 2008, 111:1774e1780
13. Kreuzer KA, Lass U, Bohn A, Landt O, Schmidt CA: LightCycler
technology for the quantitation of bcr/abl fusion transcripts. Cancer
Res 1999, 59:3171e3174
14. Wang YL, Bagg A, Pear W, Nowell PC, Hess JL: Chronic myelog-
enous leukemia: laboratory diagnosis and monitoring. Genes Chro-
mosomes Cancer 2001, 32:97e111
15. Giles FJ: Molecular monitoring of BCR-ABL transcripts: standardi-
zation needed to properly use, and further investigate the value of,
a critical surrogate marker for success in therapy of chronic myeloid
leukemia. US Oncol Hematol 2011, 7:138e142
16. Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Soverini S:
Response deﬁnitions and European Leukemianet Management
recommendations. Best Pract Res Clin Haematol 2009, 22:331e341
17. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C,
Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R,
Zoellner U, Talpaz M, Druker B, Goldman J, O’Brien SG, Russell N,
Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C,
Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A,
Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E:
Hematologic and cytogenetic responses to imatinib mesylate in
chronic myelogenous leukemia. N Engl J Med 2002, 346:645e652
18. Jabbour E, Kantarjian H, O’Brien S, Shan J, Quintas-Cardama A,
Faderl S, Garcia-Manero G, Ravandi F, Rios MB, Cortes J: The
achievement of an early complete cytogenetic response is a major
determinant for outcome in patients with early chronic phase chronic
myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011,
118:4541e4546;quiz 4759The Journal of Molecular Diagnostics - jmd.amjpathol.org19. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A,
Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC,
Goldman JM, Radich JP: Frequency of major molecular responses to
imatinib or interferon alfa plus cytarabine in newly diagnosed chronic
myeloid leukemia. N Engl J Med 2003, 349:1423e1432
20. Cortes J, Talpaz M, O’Brien S, Jones D, Luthra R, Shan J, Giles F,
Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H:
Molecular responses in patients with chronic myelogenous leukemia
in chronic phase treated with imatinib mesylate. Clin Cancer Res
2005, 11:3425e3432
21. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C,
Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N,
Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM:
Nilotinib versus imatinib for newly diagnosed chronic myeloid
leukemia. N Engl J Med 2010, 362:2251e2259
22. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW,
Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE,
Gallagher NJ, Saglio G, Kantarjian HM: Nilotinib vs imatinib in
patients with newly diagnosed Philadelphia chromosome-positive
chronic myeloid leukemia in chronic phase: eNESTnd 3-year
follow-up. Leukemia 2012, 26:2197e2203
23. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M,
Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F,
Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C,
Szatrowski T, Shapiro D, Baccarani M: Dasatinib versus imatinib in
newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J
Med 2010, 362:2260e2270
24. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB,
Undurraga MS, Wang J, Ipina JJ, Kim DW, Ogura M, Pavlovsky C,
Junghanss C, Milone JH, Nicolini FE, Robak T, Van
Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C,
Hochhaus A: Dasatinib or imatinib in newly diagnosed chronic-phase
chronic myeloid leukemia: 2-year follow-up from a randomized phase
3 trial (DASISION). Blood 2012, 119:1123e1129
25. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F,
Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J,
Rousselot P: Discontinuation of imatinib in patients with chronic
myeloid leukaemia who have maintained complete molecular remis-
sion for at least 2 years: the prospective, multicentre Stop Imatinib
(STIM) trial. Lancet Oncol 2010, 11:1029e1035
26. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O,
Blanchet O, Marit G, Gluckman E, Reiffers J, Gardembas M,
Mahon FX: Imatinib mesylate discontinuation in patients with
chronic myelogenous leukemia in complete molecular remission for
more than 2 years. Blood 2007, 109:58e60
27. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A: Stan-
dardized deﬁnitions of molecular response in chronic myeloid
leukemia. Leukemia 2012, 26:2172e2175
28. Hughes TP, Branford S: Monitoring disease response to tyrosine
kinase inhibitor therapy in CML. Hematology Am Soc Hematol Educ
Program 2009:477e487
29. Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S,
Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M,
Gathmann I, Hughes TP, Larson RA: Six-year follow-up of patients
receiving imatinib for the ﬁrst-line treatment of chronic myeloid
leukemia. Leukemia 2009, 23:1054e1061
30. Ross DM, Branford S, Moore S, Hughes TP: Limited clinical value of
regular bone marrow cytogenetic analysis in imatinib-treated chronic
phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia
2006, 20:664e670
31. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN,
Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by
BCR-ABL gene mutation or ampliﬁcation. Science 2001, 293:
876e880
32. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J,
Sawyers CL: Multiple BCR-ABL kinase domain mutations confer
polyclonal resistance to the tyrosine kinase inhibitor imatinib563
Zhen and Wang(STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Cancer Cell 2002, 2:117e125
33. Shah NP, Sawyers CL: Mechanisms of resistance to STI571 in
Philadelphia chromosome-associated leukemias. Oncogene 2003, 22:
7389e7395
34. Apperley JF: Part I: mechanisms of resistance to imatinib in chronic
myeloid leukaemia. Lancet Oncol 2007, 8:1018e1029
35. Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K,
Press R, Quigley N, Rothberg P, Sabath D, Viswanatha D, Weck K,
Zehnder J: Laboratory practice guidelines for detecting and reporting
BCR-ABL drug resistance mutations in chronic myelogenous
leukemia and acute lymphoblastic leukemia: a report of the Associ-
ation for Molecular Pathology. J Mol Diagn 2009, 11:4e11
36. Apperley JF: Part II: management of resistance to imatinib in chronic
myeloid leukaemia. Lancet Oncol 2007, 8:1116e1128
37. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J,
Taylor K, Herrmann R, Seymour JF, Arthur C, Joske D, Lynch K,
Hughes T: Detection of BCR-ABL mutations in patients with CML
treated with imatinib is virtually always accompanied by clinical
resistance, and mutations in the ATP phosphate-binding loop (P-loop)
are associated with a poor prognosis. Blood 2003, 102:276e283
38. Radich JP: The biology of CML blast crisis. Hematology Am Soc
Hematol Educ Program 2007:384e391
39. Aguayo A, Couban S: State-of-the-art in the management of chronic
myelogenous leukemia in the era of the tyrosine kinase inhibitors:
evolutionary trends in diagnosis, monitoring and treatment. Leuk
Lymphoma 2009, 50(Suppl 2):1e8
40. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I,
O’Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T,
Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M:
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
N Engl J Med 2012, 367:2075e2088
41. Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H,
Reid AG, Foroni L, Rezvani K, Bua M, Dazzi F, Pavlu J,
Klammer M, Kaeda JS, Goldman JM, Apperley JF: European Leu-
kemiaNet criteria for failure or suboptimal response reliably identify
patients with CML in early chronic phase treated with imatinib whose
eventual outcome is poor. Blood 2008, 112:4437e4444
42. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B,
Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M,
Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H,
Larson R, Niederwieser D, Silver R, Hehlmann R: Evolving concepts
in the management of chronic myeloid leukemia: recommendations
from an expert panel on behalf of the European LeukemiaNet. Blood
2006, 108:1809e1820
43. Akard LP, Wang YL: Translating trial-based molecular monitoring
into clinical practice: importance of international standards and
practical considerations for community practitioners. Clin Lymphoma
Myeloma Leuk 2011, 11:385e395
44. Zhang T, Grenier S, Nwachukwu B, Wei C, Lipton JH, Kamel-
Reid S: Inter-laboratory comparison of chronic myeloid leukemia
minimal residual disease monitoring: summary and recommenda-
tions. J Mol Diagn 2007, 9:421e430
45. College of American Pathologists (CAP). Minimal Residual Disease
(MRD-A) Survey 2012. 2012, Northﬁeld, IL
46. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J,
Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D,
Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G,564Saglio G, Soverini S, Stock W, Goldman JM: Monitoring CML
patients responding to treatment with tyrosine kinase inhibitors:
review and recommendations for harmonizing current methodology
for detecting BCR-ABL transcripts and kinase domain mutations and
for expressing results. Blood 2006, 108:28e37
47. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J,
Goldman J, Hughes T: Rationale for the recommendations for
harmonizing current methodology for detecting BCR-ABL transcripts
in patients with chronic myeloid leukaemia. Leukemia 2006, 20:
1925e1930
48. Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A,
Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, Wang YL,
Press RD, Lynch K, Rudzki Z, Goldman JM, Hughes T: Desirable
performance characteristics for BCR-ABL measurement on an
international reporting scale to allow consistent interpretation of
individual patient response and comparison of response rates between
clinical trials. Blood 2008, 112:3330e3338
49. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der
Schoot E,Delabesse E,Macintyre E,Gottardi E, SaglioG,Watzinger F,
Lion T, van Dongen JJ, Hokland P, Gabert J: Evaluation of candidate
control genes for diagnosis and residual disease detection in leukemic
patients using “real-time” quantitative reverse-transcriptase poly-
merase chain reaction (RQ-PCR): a Europe against cancer program.
Leukemia 2003, 17:2474e2486
50. Wang YL, Lee JW, Cesarman E, Jin DK, Csernus B: Molecular
monitoring of chronic myelogenous leukemia: identiﬁcation of the
most suitable internal control gene for real-time quantiﬁcation of
BCR-ABL transcripts. J Mol Diagn 2006, 8:231e239
51. Lee JW, Chen Q, Knowles DM, Cesarman E, Wang YL: beta-
Glucuronidase is an optimal normalization control gene for molecular
monitoring of chronic myelogenous leukemia. J Mol Diagn 2006, 8:
385e389
52. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y,
Branford S, Muller MC, Beauﬁls N, Beillard E, Colomer D,
Dvorakova D, Ehrencrona H, Goh HG, El Housni H, Jones D,
Kairisto V, Kamel-Reid S, Kim DW, Langabeer S, Ma ES, Press RD,
Romeo G, Wang L, Zoi K, Hughes T, Saglio G, Hochhaus A,
Goldman JM, Metcalfe P, Cross NC: Establishment of the ﬁrst World
Health Organization International Genetic Reference Panel for
quantitation of BCR-ABL mRNA. Blood 2010, 116:e111ee117
53. Cross NC: Standardisation of molecular monitoring for chronic
myeloid leukaemia. Best Pract Res Clin Haematol 2009, 22:355e365
54. Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T,
Hehlmann R, Branford S, Saglio G, Hochhaus A: Harmonization of
molecular monitoring of CML therapy in Europe. Leukemia 2009,
23:1957e1963
55. Saldanha J, Silvy M, Beauﬁls N, Arlinghaus R, Barbany G,
Branford S, Cayuela JM, Cazzaniga G, Gonzalez M, Grimwade D,
Kairisto V, Miyamura K, Lawler M, Lion T, Macintyre E, Mahon FX,
Muller MC, Ostergaard M, Pfeifer H, Saglio G, Sawyers C,
Spinelli O, van der Velden VH, Wang JQ, Zoi K, Patel V, Phillips P,
Matejtschuk P, Gabert J: Characterization of a reference material for
BCR-ABL (M-BCR) mRNA quantitation by real-time ampliﬁcation
assays: towards new standards for gene expression measurements.
Leukemia 2007, 21:1481e1487
56. Moravcova J, Rulcova J, Polakova KM, Klamova H: Control genes in
international standardization of real-time RT-PCR for BCR-ABL.
Leukemia Res 2009, 33:582e584jmd.amjpathol.org - The Journal of Molecular Diagnostics
